Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study

Modern Rheumatology

Volumn 19, Issue 6, 2009, Pages 606-615

  Miyasaka, Nobuyuki ^a   Kawai, Shinichi ^b   Hashimoto, Hiroshi ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Immunosuppressive drugs; Lupus nephritis; Randomized controlled trial; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TACROLIMUS;

ACUTE HEART INFARCTION; ADULT; ALBUMIN BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CARDIOVASCULAR DISEASE; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSMENORRHEA; ENTEROCOLITIS; FEMALE; FOLLICULITIS; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PYURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINALYSIS; VAGINITIS; WEIGHT GAIN;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COMPLEMENT C3; CREATININE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME; URINALYSIS;

EID: 73349090238     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0218-5     Document Type: Article

References (34)

1. JE Balow HA Austin III 2004 Maintenance therapy for lupus nephritis-something old, something new N Eng J Med 350 1044 1046 10.1056/NEJMe048010 1:CAS:528:DC%2BD2cXhvFGjsL0%3D (Pubitemid 38269282)
2. DG Kuiper-Geertsma RH Derksen 2003 Newer drugs for the treatment of lupus nephritis Drugs 63 167 180 10.2165/00003495-200363020-00004 1:CAS:528:DC%2BD3sXhsFCjsLg%3D 12515564 (Pubitemid 36143343)
3. DT Boumpas HA Austin 3rd EM Vaughn JH Klippel AD Steinberg CH Yarboro, et al. 1992 Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 340 741 745 10.1016/0140-6736(92)92292-N 1:STN:280:DyaK38vgvVentQ%3D%3D 1356175
4. FF Hejaili LM Moist WF Clark 2003 Treatment of lupus nephritis Drugs 63 257 274 10.2165/00003495-200363030-00002 1:CAS:528:DC%2BD3sXhslWkur0%3D 12534331 (Pubitemid 36197499)
5. G Contreras E Tozman N Nahar D Metz 2005 Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide Lupus 14 Suppl. 1 s33 s38 10.1177/ 096120330501400107 1:CAS:528:DC%2BD2MXjtlaks78%3D 15803929
6. DT Felson J Anderson 1984 Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis N Engl J Med 311 1528 1533 1:STN:280: DyaL2M%2FmtFeltg%3D%3D 6390198
7. TM Chan FK Li CS Tang RW Wong GX Fang YL Ji, et al. 2000 Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group N Engl J Med 343 1156 1162 10.1056/NEJM200010193431604 1:CAS:528:DC%2BD3cXnsleqs7w%3D 11036121 (Pubitemid 30781986)
8. EM Ginzler MA Dooley C Aranow MY Kim J Buyon JT Merrill, et al. 2005 Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 2219 2228 10.1056/NEJMoa043731 1:CAS:528:DC%2BD2MXht1GrsLbJ 16306519 (Pubitemid 41697285)
9. C Dostál V Tesar I Rychlík J Zabka J Venocovský J Bartûnková, et al. 1998 Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study Lupus 7 29 36 10.1191/096120398678919714 9493146 (Pubitemid 28052659)
10. M Tokuda N Kurata A Mizoguchi M Inoh K Seto M Kinashi, et al. 1994 Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity Arthritis Rheum 37 551 558 10.1002/art.1780370416 1:STN:280:DyaK2c7pslOruw%3D%3D 8147933
11. D Hallegua DJ Wallace AL Metzger RZ Rinaldi JR Klinenberg 2000 Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature Lupus 9 241 251 10.1191/096120300680198935 1:CAS:528:DC%2BD3cXktFKjtLg%3D 10866094
12. LS Tam EK Li CB Leung KC Wong FM Lai A Wang, et al. 1998 Long-term treatment of lupus nephritis with cyclosporin A Q J M 91 573 580 1:STN:280:DyaK1M7gvFOmuw%3D%3D
13. T Konishi Y Yoshiyama M Takamori K Yagi E Mukai T Saida 2003 Clinical study of FK506 in patients with myasthenia gravis Muscle Nerve 28 570 574 10.1002/mus.10472 1:CAS:528:DC%2BD3sXpsl2rsL0%3D 14571458 (Pubitemid 37339910)
14. T Konishi Y Yoshiyama M Takamori T Saida 2005 Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus) J Neurol Neurosurg Psychiatr 76 448 450 10.1136/jnnp.2004.042176 1:STN:280:DC%2BD2M%2Fos12jug%3D%3D 15716549 (Pubitemid 40299146)
15. K Kitahara S Kawai 2007 Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis Curr Opin Rheumatol 19 238 245 10.1097/BOR.0b013e328099af80 1:CAS:528:DC%2BD2sXjvFClt70%3D 17414949 (Pubitemid 46597460)
16. H Nakagawa T Etoh Y Ishibashi Y Higaki M Kawashima H Torii, et al. 1994 Tacrolimus ointment for atopic dermatitis Lancet 344 883 10.1016/S0140-6736(94) 92855-X 1:STN:280:DyaK2czns1GmsQ%3D%3D 7522297
17. K Takabayashi T Koike K Kurasawa R Matsumura T Sato H Tomioka, et al. 1989 Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus Clin Immunol Immunopathol 51 110 117 10.1016/0090-1229(89)90211-0 1:CAS:528:DyaL1MXktFOhu7w%3D 2466594 (Pubitemid 19096341)
18. M Duddridge RJ Powell 1997 Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases Ann Rheum Dis 56 690 692 10.1136/ard.56.11.690 1:CAS:528:DyaK1cXltVKn 9462174
19. CC Mok KH Tong CH To YP Siu TC Au 2005 Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study Kidney Int 68 813 817 10.1111/j.1523-1755.2005.00461.x 1:CAS:528:DC%2BD2MXpt1Wmur8%3D 16014060 (Pubitemid 43323138)
20. EM Tan AS Cohen JF Fries AT Masi DJ McShane NF Rothfield, et al. 1982 The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1271 1277 10.1002/art.1780251101 1:STN:280: DyaL3s%2FkvVCmtA%3D%3D 7138600 (Pubitemid 13221242)
21. C Bomberdier DD Gladman MB Urowitz D Caron CH Chang 1992 Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 35 630 640 10.1002/art.1780350606
22. S Matsuo E Imai M Horio Y Yasuda K Tomita K Nitta, et al. 2009 Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 6 932 935 10.1053/j.ajkd.2008.12.034
23. JN Siegel 1999 Development of an FDA guidance document for clinical trials in SLE Lupus 8 581 585 10.1191/096120399680411425 1:STN:280: DC%2BD3c%2FjvVaiug%3D%3D 10568893 (Pubitemid 29520522)
24. L Fraenkel T MacKenzie L Joseph M Kashigarian JP Hayslett JM Esdaile 1994 Response to treatment as a predictor of long-term outcome in patients with lupus nephritis J Rheumatol 21 2052 2057 1:STN:280:DyaK2M7ntlyqtQ%3D%3D 7869309
25. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992;19:473-9.
26. S Jacobsen H Starklint J Petersen S Ullman P Junker A Voss, et al. 1999 Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine Scand J Rheumatol 28 288 299 10.1080/03009749950155472 1:STN:280:DC%2BD3c%2FjtlSksQ%3D%3D 10568425 (Pubitemid 29491401)
27. JM Esdaile C Levinton W Federgreen JP Hayslett M Kashigarian 1989 The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature Q J Med 72 779 833 1:STN:280:DyaK3c7jvFCgug%3D%3D 2694209
28. H Bootsma P Spronk R Derksen G de Boer H Wolters-Dicke, et al. 1995 Prevention of relapses in systemic lupus erythematosus Lancet 345 1595 1599 10.1016/S0140-6736(95)90114-0 1:STN:280:DyaK2Mzgt1ymug%3D%3D 7783536
29. RS Laitman D Glicklich LB Sablay AI Grayzel P Barland N Bank 1989 Effect of long-term normalization of serum complement levels on the course of lupus nephritis Am J Med 87 132 138 1:STN:280:DyaL1MzjtlOksA%3D%3D 2757054
30. W Lloyd PH Schur 1981 Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE) Medicine 60 208 288 10.1097/00005792-198105000-00004 1:STN:280:DyaL3M7ps1Oluw%3D%3D 7231154
31. Nagamatsu T, Kojima N, Kondo N, Hattori T, Kojima R, Ito M, et al. Suppression by cyclosporin A of anti-GBM nephritis in rats. Jpn J Pharmacol. 1992;58(1):27.
32. C Faul M Donnellly S Merscher-Gomez YH Chang S Franz J Delfgaauw, et al. 2008 The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A Nature Medicine 14 931 938 10.1038/nm.1857 1:CAS:528:DC%2BD1cXhtVyms7%2FJ 18724379
33. PW Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel 1998 Prediction of coronary heart disease using risk factor categories Circulation 97 1837 1847 1:STN:280:DyaK1c3msVOjsA%3D%3D 9603539
34. JM Esdaile M Abrahamowicz T Grodzicky Y Li C Panaritis R du Berger, et al. 2001 Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus Arthritis Rheum 44 2331 2337 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I 1:STN:280:DC%2BD3MrmsVOjsg%3D%3D 11665973 (Pubitemid 32977500)